Table 2.
Unadjusted and adjusted relative risk of receiving chemotherapy based on demographic factors
| Demographic | RR of receiving chemotherapy (95% CI), univariate |
RR of receiving chemotherapy (95% CI), multivariable* |
|---|---|---|
| Sex | ||
| Male | 1.00 | 1.00 |
| Female | 0.86 (0.83–0.88) | 0.91 (0.88–0.94) |
| Age | ||
| <70 | 1.00 | 1.00 |
| >= 70 | 0.59 (0.57–0.60) | 0.59 (0.58–0.61) |
| Race | ||
| White | 1.00 | 1.00 |
| Black | 0.86 (0.82–0.90) | 0.89 (0.84–0.94) |
| Other | 1.03 (0.95–1.12) | 1.05 (0.96–1.14) |
| Location/Region | ||
| South | 1.00 | 1.00 |
| Northeast | 1.01 (0.98–1.05) | 1.00 (0.96–1.04) |
| West | 1.00 (0.96–1.03) | 0.95 (0.91–0.99) |
| Midwest | 1.06 (1.02–1.10) | 1.03 (0.99–1.07) |
| Median Household Income | ||
| $46,000+ | 1.00 | 1.00 |
| $35,000–45,999 | 0.96 (0.93–0.99) | 0.98 (0.94–1.01) |
| $30,000–34,999 | 0.93 (0.90–0.97) | 0.97 (0.92–1.01) |
| <$30,000 | 0.87 (0.83–0.90) | 0.94 (0.89–1.00) |
| Education, % of people in patient’s area graduate high school |
||
| <14% | 1.00 | 1.00 |
| 14–19.9% | 0.97 (0.94–1.01) | 0.99 (0.95–1.02) |
| 20–28.9% | 0.94 (0.91–0.97) | 0.95 (0.91–0.99) |
| 29% or more | 0.86 (0.82–0.89) | 0.88 (0.84–0.93) |
| Insurance | ||
| Yes | 1.00 | 1.00 |
| No | 1.11 (1.05–1.18) | 0.92 (0.86–0.98) |
| Facility Type | ||
| Community Program | 1.00 | 1.00 |
| Academic/Research Program | 1.06 (1.03–1.09) | 0.98 (0.95–1.01) |
| Other | 0.92 (0.83–1.03) | 0.93 (0.82–1.04) |
| Charlson-Deyo Score | ||
| 0 | 1.00 | 1.00 |
| 1 | 0.84 (0.80–0.87) | 0.89 (0.85–0.92) |
| 2 | 0.70 (0.65–0.75) | 0.74 (0.68–0.80) |
| Unknown | 0.87 (0.84–0.89) | 0.86 (0.80–0.92) |
| Histology | ||
| Urothelial | 1.00 | 1.00 |
| Other | 0.84 (0.80–0.89) | 0.84 (0.80–0.89) |
| Unknown | 0.61 (0.56–0.67) | 0.70 (0.64–0.77) |
| Clinical T stage | ||
| 2 | 1.00 | 1.00 |
| 3 | 1.04 (0.99–1.08) | 0.99 (0.94–1.03) |
| 4 | 0.92 (0.89–0.95) | 0.96 (0.92–0.99) |
| Other/Unknown | 0.88 (0.85–0.90) | 0.93 (0.89–0.97) |
| Clinical N stage | ||
| 0 | 1.00 | 1.00 |
| 1 | 1.24 (1.19–1.29) | 1.22 (1.17–1.28) |
| 2 | 1.27 (1.22–1.32) | 1.23 (1.18–1.28) |
| 3 | 1.19 (1.10–1.29) | 1.20 (1.10–1.30) |
| Unable to be assessed | 0.97 (0.94–1.00) | 1.00 (0.96–1.04) |
| Presence of distant metastases | ||
| No | 1.00 | 1.00 |
| Yes | 0.89 (0.86–0.91) | 0.92 (0.89–0.95) |
| Cystectomy Performed | ||
| No | 1.00 | 1.00 |
| Yes | 1.09 (1.06–1.12) | 0.98 (0.95–1.01) |
*
Adjusted for sex, age, year of diagnosis, race, insurance status, distance to facility, location of facility, income, education, facility type, comorbidity score, histology, cystectomy, clinical T stage, and presence of nodal and distant metastases. N=20,571 included in the model, with complete data for all covariates.
RR = relative risk, CI = confidence interval